News Breaks |
|
|
| September 13, 2012 |
| 08:32 EDT |  | DARA | Dara BioSciences granted exclusive U.S. commercial rights to Gelclair by Helsinn
Dara BioSciences has entered into an exclusive agreement with The Helsinn Group of Switzerland for U.S. commercial rights to Gelclair. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis. DARA plans to launch Gelclair in Q1 2013. |
|
|
News For DARA From The Last 14 Days Check below for free stories on DARA the last two weeks. |
|
|
| June 18, 2013 |
| 08:11 EDT | | DARA | Dara BioSciences grants T3D Therapeutics worldwide rights to commercialize DB959
Dara BioSciences announced that it has granted T3D Therapeutics the exclusive worldwide rights to develop and commercialize DB959. DB959 is an oral, highly selective, dual nuclear receptor agonist whose primary target is PPARd. DARA had previously developed DB959 through Phase 1 clinical trials for the treatment of diabetes and dyslipidemia. |
|
|
|
|
|
